Loading organizations...
§ Private Profile · North Andover, MA, USA
OncoPep is a company.
OncoPep has raised $20.4M across 3 funding rounds.
Key people at OncoPep.
OncoPep has raised $20.4M in total across 3 funding rounds.
OncoPep develops targeted immunotherapeutics, including cancer vaccines and adoptive T-cell therapies, aimed at preventing cancer progression. Their approach leverages multi-tumor antigen strategies to prolong patient survival and enhance quality of life, advancing novel treatments for various cancers. The company actively advances its pipeline through clinical trials and strategic licensing agreements for innovative therapeutic platforms.
The company was founded in 2010, based on technology developed by Drs. Kenneth Anderson, Nikhil Munshi, and David Avigan. Mark Cohen also co-founded OncoPep, taking on the role of chairman, with the foundational insight stemming from the potential to commercialize these advanced therapeutic approaches for oncology patients who critically need new treatment options.
OncoPep primarily serves patients facing difficult-to-treat cancers, including those like metastatic triple-negative breast cancer, by developing innovative immunotherapy solutions. The company's vision is to bring forward a pipeline of effective therapies that significantly impact disease outcomes, providing new hope and improved prognosis for cancer patients worldwide.
Key people at OncoPep.
OncoPep has raised $20.4M in total across 3 funding rounds.
OncoPep's investors include Kukje Pharma, Tera Science, CrystalBioScience, SX Company, Keting Chu.
OncoPep has raised $20.4M across 3 funding rounds. Most recently, it raised $11.0M Series D in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 9, 2021 | $11M Series D | Kukje Pharma, Tera Science | Crystalbioscience, SX Company | Announced |
| Aug 28, 2014 | $6.9M Series B | Keting CHU | — | Announced |
| Apr 26, 2012 | $2.5M Venture Round | — | — | Announced |
OncoPep is a biotechnology company developing targeted immunotherapeutics, including cancer vaccines and cell therapies, to train the immune system against cancer cells, primarily focusing on multiple myeloma and other cancers.[2][3][5] Its lead program is a therapeutic cancer vaccine for smoldering multiple myeloma, with additional candidates like PVX-410 (targeting CD138, SLAMF7, XBP1) in Phase 1 and others in early stages for solid tumors and hematologic malignancies.[3][6] OncoPep serves patients with hard-to-treat cancers such as multiple myeloma, melanoma, lung, breast, and prostate cancers, addressing unmet needs by offering precise treatments with fewer side effects than chemotherapy or radiation, often combinable with checkpoint inhibitors.[3][6] The company has raised $22.05M total, including a $11M Series D and earlier $6.9M Series B, showing steady funding momentum in the growing peptide cancer vaccine market projected at 48% CAGR to $5.9B by 2032.[3][7]
OncoPep, Inc. was founded in 2010 in North Andover, Massachusetts, to commercialize a novel approach to targeted immunotherapeutics against cancer, building on synthetic, recombinant, and naturally derived peptide vaccines.[3][5] The company's emergence tied to advancing immunotherapy for cancers like multiple myeloma, with early efforts supported by funding from organizations like the Leukemia & Lymphoma Society (now Blood Cancer United).[7][8] Pivotal moments include a $6.9M Series B in prior years to advance vaccines and recent pipeline expansion with multi-tumor antigen adoptive T-cell therapy, strengthening its focus on blood cancers.[7][8] This trajectory reflects a commitment to prolonging survival and quality of life in progressing cancers.[2]
(Note: OncoPep is distinct from Oncopeptides, a separate Swedish firm with marketed drug Pepaxti.[1][4])
OncoPep rides the immunotherapy wave, particularly peptide cancer vaccines and adoptive T-cell therapies, amid surging demand for personalized, low-toxicity cancer treatments in a market expanding at over 10-48% CAGR through 2032-2035.[3] Timing aligns with advancements in immune checkpoint combinations and real-world data showing efficacy in advanced melanoma and multiple myeloma, fueled by market forces like rising cancer incidence and immunotherapy adoption over chemotherapies.[3][6] It influences the ecosystem by targeting underserved blood cancers via partnerships (e.g., Leukemia & Lymphoma Society funding) and contributing to pipelines for hospitals and research centers, amplifying precision oncology's shift toward combinable, patient-centric therapies.[3][7][8]
OncoPep's next milestones likely include Phase 1 readouts for PVX-410 and T-cell expansions, potentially advancing to later trials amid a booming peptide vaccine sector.[3][6][8] Trends like AI-driven personalization and combo immunotherapies will shape its path, with market growth favoring agile biotechs like OncoPep over incumbents. Its influence may evolve from niche multiple myeloma innovator to broader solid-tumor player, delivering targeted hope in cancer care—echoing its mission to prevent progression and restore lives.[2]
